行情

NVIV

NVIV

InVivo
NASDAQ

实时行情|Nasdaq Last Sale

0.5000
+0.0353
+7.60%
已收盘, 16:00 10/14 EDT
开盘
0.4901
昨收
0.4647
最高
0.5000
最低
0.4900
成交量
2.44万
成交额
--
52周最高
2.750
52周最低
0.4500
市值
465.59万
市盈率(TTM)
-0.3800
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NVIV 新闻

  • 加州州长要求太平洋瓦电对上周大面积停电负责
  • 新浪美股.2小时前
  • 安永:中国对外直接投资跻身全球第一梯队
  • 中国新闻网.3小时前
  • 毕马威全球颠覆者报告:阿里巴巴等六家中国公司上榜
  • 新浪财经综合.3小时前
  • 数据:伦交所环球板交易工具(CDI)
  • 新浪财经.3小时前

更多

所属板块

先进医疗设备和技术
+0.33%
医疗设备和用品
+0.06%

热门股票

名称
价格
涨跌幅

NVIV 简况

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
展开

Webull提供Invivo Therapeutics Holdings Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。